Amneal Pharmaceuticals, Inc.
AMRXNASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 15, 2026 close
- Market cap
- $6.32B
- P/E (TTM)
- 40.14
- Forward P/E
- 19.98
- Dividend yield
- -
- 52-week range
- $9.56$21.18
- Volume (live)
- -
- Avg. volume (3M)
- 2.87M
Amneal Pharmaceuticals (AMRX) Stock Price & Financial Analysis
Amneal Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $18.94 - $19.39 |
|---|---|
| 52-Week High | $21.18 |
| 52-Week Low | $9.56 |
| Open | $19.28 |
| Volume (last close) | 2.29M |
| Average Volume (3M) | 2.87M |
| Revenue (TTM) | 3.12B |
|---|---|
| Net Income (TTM) | 157.36M |
| Free Cash Flow (TTM) | 75.69M |
| EPS (TTM) | $0.48 |
| Profit Margin | 5.05% |
| Operating Margin | 14.68% |
| Return on Equity (ROE) | 476.51% |
| Debt to Equity | 84.54 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 6.32B |
|---|---|
| Shares Outstanding | 328.10M |
| P/E Ratio (TTM) | 40.14 |
| Forward P/E | 19.98 |
| Price to Sales (P/S) | 2.03 |
| Price to Book (P/B) | 191.25 |
| EV/EBITDA | 13.77 |
| 50-Day MA | $18.53 |
|---|---|
| 200-Day MA | $15.29 |
| 1-Year Change | +95.04% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Amneal Pharmaceuticals at a Glance
As of the Oct 16, 2026 close, Amneal Pharmaceuticals (AMRX) has a market capitalization of $6.32B. The stock trades at 40.1× trailing earnings, 20.0× forward earnings and 2.0× sales. Over the trailing twelve months it earned $157.36M on revenue of $3.12B (a 5.0% profit margin) and generated $75.69M of free cash flow. Revenue grew 9.3% year over year.
As of its latest reported balance sheet, it holds $127.64M in cash and securities against $2.79B of debt, a net debt position of $2.66B.
Amneal Pharmaceuticals does not currently pay a dividend.
The share price is up 95.0% over the past year. At $19.18 (the Oct 16, 2026 close) it sits within its 52-week range of $9.56 to $21.18, above its 200-day moving average of $15.29.
Based on 9 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $22.17, 15.6% above the Oct 16, 2026 close.
Frequently Asked Questions About Amneal Pharmaceuticals
What is the current stock price for AMRX?
As of the Oct 16, 2026 close, AMRX stock trades at $19.18. The 52-week range is $9.56–$21.18, with a day range of $18.94–$19.39.
What is the P/E ratio for AMRX?
As of the Oct 16, 2026 close, Amneal Pharmaceuticals's trailing twelve-month (TTM) P/E ratio is 40.1, meaning investors pay $40.1 for every $1 of annual earnings. The forward P/E is 20.0, reflecting analyst expectations for future earnings. Amneal Pharmaceuticals operates in the Healthcare sector.
Does AMRX pay dividends?
Amneal Pharmaceuticals does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for AMRX?
Based on ratings from 9 professional analysts over the last 90 days, the consensus for AMRX is Buy. The average 12-month price target is $22.17, a 15.6% upside from the Oct 16, 2026 close of $19.18.
What is the market cap of AMRX?
As of the Oct 16, 2026 close, Amneal Pharmaceuticals's market capitalization is $6.29B, classifying it as a mid-cap company. Amneal Pharmaceuticals operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.